Placental MSC benefit typically persists for 12–36 months; some patients maintain improvement longer, while others experience gradual recurrence. HSCT-induced remissions have been sustained for 5+ years in published series, though late relapse is possible. Neither therapy cures scleroderma; disease remission appears to be achieved, not cure.
Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins. The underlying immunological dysfunction involves autoreactive T cells, B cells producing pathogenic antibodies (anti-topoisomerase, anti-centromere), and dysregulated cytokine signalling (TGF-β, IL-6). Placental MSCs are being explored as an anti-inflammatory and immunomodulatory intervention, delivering cytokines and cell-surface molecules that suppress autoreactive immune cells and potentially reprogram fibroblast behaviour. Unlike conventional disease-modifying antirheumatic drugs (DMARDs), cell therapy aims to reset immune tolerance rather than merely suppress inflammation. Note: autologous haematopoietic stem-cell transplantation (HSCT) is an established, though intensive, option for severe early-stage systemic sclerosis in selected candidates, with demonstrated benefit in some clinical series.
Sono un candidato? → · Scleroderma (Systemic Sclerosis): full overview → · Costo Sclerodermia (Sclerosi Sistemica) → · Cost →
Rivisto medicalmente dal team editoriale di StemCellAtlas con Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) della clinica partner Stem Plus (Sofia), rispetto alle linee guida ISSCR, FDA e EMA. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita